Recent evidence suggests that a variety of environmental factors, including dietary and gastrointestinal agents, may contribute to autism spectrum disorders (ASD). Here we administered propionic acid (PPA), a short chain fatty acid that is used as a food preservative and also is a metabolic end-product of enteric bacteria in the gut, to adolescent (41 ± 4 days) male rats in a study of restricted/repetitive behavior, social behavior, and cognition. The goal was to further evaluate the effects of PPA in young rodents. PPA (4 μl of 0.26 M solution) was administered intracerebroventricularly prior to each behavioral test. Rats treated with PPA displayed restricted behavioral interest to a specific object among a group of objects, impaired social behavior, and impaired reversal in a T-maze task compared to controls given phosphate buffered saline. Immunohistochemical analysis of brain tissue from PPA rats revealed reactive astrogliosis and activated microglia, indicating an innate neuroinflammatory response. These findings are consistent with our earlier findings of ASD-relevant behavioral and brain events in adult rats given PPA, and support further study of effects of PPA in young rodents by establishing similar effects in adolescent animals.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bbr.2010.10.005 | DOI Listing |
Alzheimers Dement
December 2024
Christ University, Bangalore, India.
Background: Research has consistently shown decreased quality of life (QoL) in people with dementia, with predictors of QoL ranging from education to emotional status. This study, along with a one year follow-up study, investigated the impact of Awe Walks as an intervention targeting emotional status for the first time in dementia. Awe-a positive emotion elicited when in the presence of vast things not immediately understood-promotes social connection and fosters well-being by encouraging a "small self".
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Universidade Federal de São Paulo (UNIFESP), São Paulo, São Paulo/SP, Brazil.
Background: Dementia awareness and education are currently limited among healthcare workers and the general public, contributing towards the generation and propagation of stigma and discrimination against people with dementia worldwide. It is crucial to promote evidence-based anti-stigma interventions with a focus on stigma reduction.
Method: This is a randomized and controlled feasibility trial of a group intervention aimed at improving knowledge and reducing stigma related to dementia among Community Health Workers (CHWs) (Trial Registration: RBR-10xp637m).
Alzheimers Dement
December 2024
Aga Khan University, Nairobi, Kenya.
Background: Population growth and an increase in the number of Africans who survive to old age puts them at a higher risk of developing neurodegenerative diseases such as dementia and Alzheimer's. Little research has been conducted on community knowledge and perceptions of dementia in rural settings in Kenya.
Method: Community health volunteers, healthcare workers (HCWs), chiefs and assistant chiefs (n = 35) participated in five focus group discussions, each comprising seven- eight people.
Alzheimers Dement
December 2024
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Background: Frontotemporal degeneration (FTD) is an umbrella term encompassing a range of rare neurodegenerative disorders that cause progressive changes to behavior, personality, language, and movement with onset typically before age 60. Currently, several potential FTD therapies are under investigation, underscoring the need for increased diversity in research participation. Two validated scores describe socioeconomic and geographic factors that may impact willingness to participate in research.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neurology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Background: Integrating blood biomarker testing for Alzheimer's Disease (AD) into clinical practice has the potential to transform AD care by enabling broadly accessible and accurate diagnosis, more precise prognostication, and timely initiation of disease-modifying therapy. While there are several scientific challenges to implementing blood biomarkers (e.g.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!